National Comprehensive Cancer Network

About NCCN

NCCN Flash Updates™: NCCN Guidelines® and NCCN Compendium® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Multiple Myeloma. These NCCN Guidelines® are currently available as Version 3.2016.

  • Staging Systems for Multiple Myeloma (MYEL-A)
    • Added the revised International Staging System (R-ISS) for multiple myeloma based on Palumbo A, Avet-Loiseau H, Oliva S, et al. J Clin Oncol 2015;33:2863-2869.
  • Myeloma Therapy (MYEL-D, 1 of 2)
    • Primary therapy for transplant and non-transplant candidates
      • The NCCN category for bortezomib/lenalidomide/dexamethasone in the list of preferred regimens was changed from category 2A to category1 based on newly published phase III trial data.
      • Ixazomib/lenalidomide/dexamethasone combination was added as an option to the list of other regimens.
  • Myeloma Therapy (MYEL-D, 2 of 2)
    • Therapy for previously treated multiple myeloma
      • The following were added as treatment options to the list of preferred regimens:
        • Daratumumab with a new footnote “Indicated for the treatment of patients who have received at least three prior therapies, including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and immunomodulatory agent.”
        • Elotuzumab/lenalidomide/dexamethasone (category 1) with a new footnote “Indicated in combination with lenalidomide and dexamethasone for the treatment of patients who have received one to three prior therapies.”
        • Ixazomib and single agent; Ixazomib in combination with dexamethasone; and ixazomib in combination with lenalidomide/dexamethasone, with a new footnote, “Indicated for the treatment of patients who have received at least one prior therapy.”
      • The following was added as treatment options to the list of other regimens:
        • Panobinostat/carfilzomib combination

*For your reference, the previous update (Version 2.2016) to the NCCN Guidelines for Multiple Myeloma, published on September 23, 2015, is available at the following link:

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit

To access the NCCN Biomarkers Compendium™, please visit

To view the NCCN Guidelines for Patients®, please visit


Free NCCN Guidelines apps for iPhone, iPad, and Android tablets are now available! Visit

About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)

275 Commerce Drive, Suite 300

Fort Washington, PA 19034

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2016 National Comprehensive Cancer Network. All Rights Reserved.